David Mutch

Research output

Research output per year 1986 2005 2006 2007 2011 2013 2014 2015 2017 2018 2019 2020 2022 2023 2023

• 406 Article
• 40 Review article
• 29 Comment/debate
• 13 Editorial
• 19 More
  • 7 Chapter
  • 4 Foreword/postscript
  • 4 Letter
  • 2 Book
  • 1 Conference contribution
  • 1 Short survey

Research output per year

Research output per year

Search results

• 2023

  Author Correction: Pan-cancer analysis of whole genomes (Nature, (2020), 578, 7793, (82-93), 10.1038/s41586-020-1969-6)

  The ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, Feb 16 2023, In: Nature. 614, 7948, p. E39

  Research output: Contribution to journal › Comment/debate

  Open Access

  • Genome 100%
  • Neoplasms 47%
  1 Scopus citations

• Author Correction: Comprehensive molecular characterization of mitochondrial genomes in human cancers (Nature Genetics, (2020), 52, 3, (342-352), 10.1038/s41588-019-0557-x)

  PCAWG Consortium, Jun 2023, In: Nature Genetics. 55, 6, p. 1078 1 p.

  Research output: Contribution to journal › Comment/debate

  Open Access

  • Mitochondrial Genome 100%
  • Genome 53%
  • Neoplasms 25%

• Author Correction: Pan-cancer analysis of whole genomes identifies driver rearrangements promoted by LINE-1 retrotransposition (Nature Genetics, (2020), 52, 3, (306-319), 10.1038/s41588-019-0562-0)

  PCAWG-Structural Variation Working Group & PCAWG Consortium, Jun 2023, In: Nature Genetics. 55, 6, p. 1080 1 p.

  Research output: Contribution to journal › Comment/debate

  Open Access

  • Genome 100%
  • Medicine 53%
  • Neoplasms 47%
  • Baltimore 47%
  • Quebec 44%
  1 Scopus citations

• Author Correction: Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing (Nature Genetics, (2020), 52, 3, (331-341), 10.1038/s41588-019-0576-7)

  PCAWG-Structural Variation Working Group & PCAWG Consortium, Jun 2023, In: Nature Genetics. 55, 6, p. 1076 1 p.

  Research output: Contribution to journal › Comment/debate

  Open Access

  • Chromothripsis 100%
  • Whole Genome Sequencing 67%
  • Genome 39%
  • Neoplasms 18%

• Author Correction: Disruption of chromatin folding domains by somatic genomic rearrangements in human cancer (Nature Genetics, (2020), 52, 3, (294-305), 10.1038/s41588-019-0564-y)

  PCAWG-Structural Variation Working Group & PCAWG Consortium, Jun 2023, In: Nature Genetics. 55, 6, p. 1079 1 p.

  Research output: Contribution to journal › Comment/debate

  Open Access

  • Chromatin 100%
  • Genome 76%
  • Neoplasms 36%

• Author Correction: The landscape of viral associations in human cancers (Nature Genetics, (2020), 52, 3, (320-330), 10.1038/s41588-019-0558-9)

  PCAWG Pathogens & PCAWG Consortium, Jun 2023, In: Nature Genetics. 55, 6, p. 1077 1 p.

  Research output: Contribution to journal › Comment/debate

  Open Access

  • Genome 100%
  • Neoplasms 47%
  • Germany 32%
  • Infections 17%

• Carboplatin dosing in the treatment of ovarian cancer: An NRG oncology group study

  Praiss, A. M., Miller, A., Smith, J., Lichtman, S. M., Bookman, M., Aghajanian, C., Sabbatini, P., Backes, F., Cohn, D. E., Argenta, P., Friedlander, M., Goodheart, M. J., Mutch, D. G., Gershenson, D. M., Tewari, K. S., Wenham, R. M., Wahner Hendrickson, A. E., Lee, R. B., Gray, H., Secord, A. A., & 2 othersVan Le, L. & O'Cearbhaill, R. E., Jul 2023, In: Gynecologic oncology. 174, p. 213-223 11 p.

  Research output: Contribution to journal › Article › peer-review

  • Carboplatin 100%
  • Ovarian Neoplasms 81%
  • Creatinine 70%
  • Kidney 27%
  • Area Under Curve 20%

• DiSaia and Creasman Clinical Gynecologic Oncology

  Creasman, W. T., Mutch, D. G., Mannel, R. S. & Tewari, K. S., Jan 1 2023, Elsevier. 680 p.

  Research output: Book/Report › Book › peer-review

  • Medical Oncology 100%
  • Patient Care 65%
  • Physicians 53%
  • Neoplasms 27%
  • Therapeutics 13%
  1 Scopus citations

• FIGO staging of endometrial cancer: 2023

  Endometrial Cancer Staging Subcommittee FIGO Women's Cancer Committee, Sep 2023, In: Journal of Gynecologic Oncology. 34, 5, e85.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Endometrial Neoplasms 100%
  • Neoplasm Metastasis 30%
  • Myometrium 28%
  • Endometrium 25%
  • Urinary Bladder Diseases 18%
  1 Scopus citations

• FIGO staging of endometrial cancer: 2023

  Endometrial Cancer Staging Subcommittee, FIGO Women's Cancer Committee, Aug 2023, In: International Journal of Gynecology and Obstetrics. 162, 2, p. 383-394 12 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Endometrial Neoplasms 100%
  • Neoplasm Metastasis 30%
  • Myometrium 28%
  • Endometrium 25%
  • Urinary Bladder Diseases 18%
  36 Scopus citations

• Genes and cancer: Genetic counselling and clinical management

  Hagemann, A. R., Nikam, R. & Mutch, D. G., Jan 1 2023, DiSaia and Creasman Clinical Gynecologic Oncology. Elsevier, p. 521-559 39 p.

  Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

  • Genetic Counseling 100%
  • Neoplasm Genes 99%
  • Oncologists 50%
  • Risk Assessment 38%
  • History 34%

• Genetic characterization of primary and metastatic high-grade serous ovarian cancer tumors reveals distinct features associated with survival

  Kotnik, E. N., Mullen, M. M., Spies, N. C., Li, T., Inkman, M., Zhang, J., Martins-Rodrigues, F., Hagemann, I. S., McCourt, C. K., Thaker, P. H., Hagemann, A. R., Powell, M. A., Mutch, D. G., Khabele, D., Longmore, G. D., Mardis, E. R., Maher, C. A., Miller, C. A. & Fuh, K. C., Dec 2023, In: Communications Biology. 6, 1, 688.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • RNA Sequencing 100%
  • ovarian neoplasms 86%
  • Lethal 71%
  • Ovarian Neoplasms 54%
  • Mutation 50%
  4 Scopus citations

• Gestational choriocarcinoma

  Bogani, G., Ray-Coquard, I., Mutch, D., Vergote, I., Ramirez, P. T., Prat, J., Concin, N., Li Ngoi, N. Y., Coleman, R. L., Enomoto, T., Takehara, K., Denys, H., Lorusso, D., Takano, M., Sagae, S., Wimberger, P., Segev, Y., Kim, S. I., Kim, J. W., Herrera, F., & 15 othersMariani, A., Brooks, R. A., Tan, D., Paolini, B., Chiappa, V., Longo, M., Raspagliesi, F., Panici, P. B., Donato, V. D., Caruso, G., Colombo, N., Pignata, S., Zannoni, G., Scambia, G. & Monk, B. J., Oct 1 2023, In: International Journal of Gynecological Cancer. 33, 10, p. 1504-1514 11 p.

  Research output: Contribution to journal › Article › peer-review

  • Choriocarcinoma 100%
  • Drug Therapy 38%
  • Gestational Trophoblastic Disease 18%
  • Disease Eradication 18%
  • Fertility Preservation 17%

• Mixed clear cell/endometrioid and clear cell/serous carcinoma of the uterus are clinicopathologically similar to pure clear cell carcinoma: An NRG Oncology/Gynecologic Oncology Group (GOG-210) study of 311 women

  Hagemann, I. S., Deng, W., Zaino, R. J., Powell, M. A., Gunderson Jackson, C., Cosgrove, C., Mathews, C., Pearl, M. L., Waggoner, S., Ghebre, R., Lele, S., Guntupalli, S., Secord, A. A., Ioffe, O., Rasty, G., Singh, M., Soslow, R., Creasman, W. & Mutch, D. G., Oct 2023, In: Gynecologic oncology. 177, p. 38-45 8 p.

  Research output: Contribution to journal › Article › peer-review

  • Uterus 100%
  • Carcinoma 71%
  • Endometrial Neoplasms 40%
  • Neoplasms 18%
  • Survival 10%

• Preface

  Creasman, W. T., Mutch, D. G., Mannel, R. S. & Tewari, K. S., Jan 1 2023, DiSaia and Creasman Clinical Gynecologic Oncology. Elsevier, p. vi-vi

  Research output: Chapter in Book/Report/Conference proceeding › Foreword/postscript

• Proteogenomic insights suggest druggable pathways in endometrial carcinoma

  Clinical Proteomic Tumor Analysis Consortium, Sep 11 2023, In: Cancer Cell. 41, 9, p. 1586-1605.e15

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Proteogenomics 100%
  • Endometrial Neoplasms 61%
  • Antigen Presentation 43%
  • Metformin 42%
  • Phosphorylation 27%

• RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer

  Compadre, A. J., van Biljon, L. N., Valentine, M. C., Llop-Guevara, A., Graham, E., Fashemi, B., Herencia-Ropero, A., Kotnik, E. N., Cooper, I., Harrington, S. P., Kuroki, L. M., McCourt, C. K., Hagemann, A. R., Thaker, P. H., Mutch, D. G., Powell, M. A., Sun, L., Mosammaparast, N., Serra, V., Zhao, P., & 3 othersLomonosova, E., Khabele, D. & Mullen, M. M., Jul 5 2023, In: Clinical cancer research : an official journal of the American Association for Cancer Research. 29, 13, p. 2466-2479 14 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Platinum 100%
  • Ovarian Neoplasms 86%
  • Biomarkers 61%
  • Drug Therapy 56%
  • Organoids 27%
  3 Scopus citations

• Stromal DDR2 Promotes Ovarian Cancer Metastasis through Regulation of Metabolism and Secretion of Extracellular Matrix Proteins

  Schab, A. M., Greenwade, M. M., Stock, E., Lomonosova, E., Cho, K., Grither, W. R., Noia, H., Wilke, D., Mullen, M. M., Hagemann, A. R., Hagemann, I. S., Thaker, P. H., Kuroki, L. M., McCourt, C. K., Khabele, D., Powell, M. A., Mutch, D. G., Zhao, P., Shriver, L. P., Patti, G. J., & 2 othersLongmore, G. D. & Fuh, K. C., 2023, In: Molecular Cancer Research. 21, 11, p. 1234-1248 15 p.

  Research output: Contribution to journal › Article › peer-review

  • Discoidin Domain Receptor 2 100%
  • Extracellular Matrix Proteins 63%
  • Ovarian Neoplasms 51%
  • Neoplasm Metastasis 34%
  • Peritoneal Cavity 18%
  1 Scopus citations

• The effect of older age on treatment outcomes in women with advanced ovarian cancer receiving chemotherapy: An NRG-Oncology/Gynecologic Oncology Group (GOG-0182-ICON5) ancillary study

  Sia, T. Y., Tew, W. P., Purdy, C., Chi, D. S., Menzin, A. W., Lovecchio, J. L., Bookman, M. A., Cohn, D. E., Teoh, D. G., Friedlander, M., Bender, D., Mutch, D. G., Gershenson, D. M., Tewari, K. S., Wenham, R. M., Wahner Hendrickson, A. E., Lee, R. B., Gray, H. J., Secord, A. A., Van Le, L., & 1 othersLichtman, S. M., Jun 2023, In: Gynecologic oncology. 173, p. 130-137 8 p.

  Research output: Contribution to journal › Article › peer-review

  • Ovarian Neoplasms 100%
  • Drug Therapy 64%
  • Ovarian Epithelial Carcinoma 31%
  • Carboplatin 30%
  • Survival 30%

• Uterine Neoplasms, Version 1.2023

  Abu-Rustum, N., Yashar, C., Arend, R., Barber, E., Bradley, K., Brooks, R., Campos, S. M., Chino, J., Chon, H. S., Chu, C., Crispens, M. A., Damast, S., Fisher, C. M., Frederick, P., Gaffney, D. K., Giuntoli, R., Han, E., Holmes, J., Howitt, B. E., Lea, J., & 17 othersMariani, A., Mutch, D., Nagel, C., Nekhlyudov, L., Podoll, M., Salani, R., Schorge, J., Siedel, J., Sisodia, R., Soliman, P., Ueda, S., Urban, R., Wethington, S. L., Wyse, E., Zanotti, K., McMillian, N. R. & Aggarwal, S., Feb 2023, In: JNCCN Journal of the National Comprehensive Cancer Network. 21, 2, p. 181-209 29 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Uterine Neoplasms 100%
  • Endometrioid Carcinoma 41%
  • Carcinoma 40%
  • Endometrial Neoplasms 31%
  • Malignant Mixed Tumor 23%
  26 Scopus citations
• 2022

  Author Correction: Integrative pathway enrichment analysis of multivariate omics data (Nature Communications, (2020), 11, 1, (735), 10.1038/s41467-019-13983-9)

  PCAWG Drivers and Functional Interpretation Working Group, PCAWG Consortium, Fulton, L. A., Fulton, R. S., Govindan, R., Jayasinghe, R., Ley, T., Miller, C. A., Mutch, D. & Wendl, M. C., Dec 1 2022, In: Nature communications. 13, 1, 7570.

  Research output: Contribution to journal › Comment/debate

  Open Access

  • genome 100%
  • document markup languages 91%
  • cancer 71%
  • Communication 69%
  • communication 63%

• Author Correction: Combined burden and functional impact tests for cancer driver discovery using DriverPower (Nature Communications, (2020), 11, 1, (734), 10.1038/s41467-019-13929-1)

  PCAWG Drivers and Functional Interpretation Working Group, PCAWG Consortium, Fulton, L. A., Fulton, R. S., Govindan, R., Jayasinghe, R., Ley, T., Miller, C. A., Mutch, D. & Wendl, M. C., Dec 1 2022, In: Nature communications. 13, 1, 7571.

  Research output: Contribution to journal › Comment/debate

  Open Access

  • impact tests 100%
  • genome 79%
  • cancer 71%
  • Communication 69%
  • communication 63%

• Author Correction: Genomic footprints of activated telomere maintenance mechanisms in cancer (Nature Communications, (2020), 11, 1, (733), 10.1038/s41467-019-13824-9)

  PCAWG-Structural Variation Working Group, PCAWG Consortium, Borst, C., Fulton, L. A., Fulton, R. S., Jayasinghe, R., Ley, T., Miller, C. A., Mutch, D. & Wendl, M. C., Dec 1 2022, In: Nature communications. 13, 1, 7574.

  Research output: Contribution to journal › Comment/debate

  Open Access

  • telomeres 100%
  • genome 76%
  • document markup languages 70%
  • footprints 66%
  • Telomere 64%

• Author Correction: Reconstructing evolutionary trajectories of mutation signature activities in cancer using TrackSig (Nature Communications, (2020), 11, 1, (731), 10.1038/s41467-020-14352-7)

  PCAWG Evolution and Heterogeneity Working Group, PCAWG Consortium, Fulton, L. A., Fulton, R. S., Govindan, R., Jayasinghe, R., Ley, T., Miller, C. A., Mutch, D. & Wendl, M. C., Dec 1 2022, In: Nature communications. 13, 1, 7567.

  Research output: Contribution to journal › Comment/debate

  Open Access

  • genome 100%
  • document markup languages 91%
  • mutations 89%
  • cancer 71%
  • Communication 69%

• Author Correction: A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns (Nature Communications, (2020), 11, 1, (728), 10.1038/s41467-019-13825-8)

  PCAWG Tumor Subtypes and Clinical Translation Working Group, PCAWG Consortium, Fulton, L. A., Fulton, R. S., Govindan, R., Jayasinghe, R., Ley, T., Miller, C. A., Mutch, D. & Wendl, M. C., Dec 2022, In: Nature communications. 13, 1, 7573.

  Research output: Contribution to journal › Comment/debate

  Open Access

  • Deep Learning 100%
  • genome 94%
  • passengers 93%
  • document markup languages 86%
  • mutations 84%

• Author Correction: Divergent mutational processes distinguish hypoxic and normoxic tumours (Nature Communications, (2020), 11, 1, (737), 10.1038/s41467-019-14052-x)

  PCAWG Consortium, Fulton, L. A., Fulton, R. S., Govindan, R., Jayasinghe, R., Ley, T., Miller, C. A., Mutch, D. & Wendl, M. C., Dec 2022, In: Nature communications. 13, 1, 7569.

  Research output: Contribution to journal › Comment/debate

  Open Access

  • genome 100%
  • document markup languages 91%
  • tumors 73%
  • cancer 71%
  • Communication 69%
  1 Scopus citations

• Author Correction: Pathway and network analysis of more than 2500 whole cancer genomes (Nature Communications, (2020), 11, 1, (729), 10.1038/s41467-020-14367-0)

  PCAWG Drivers and Functional Interpretation Working Group, PCAWG Consortium, Appelbaum, E. L., Fulton, L. A., Fulton, R. S., Govindan, R., Jayasinghe, R., Ley, T., Miller, C. A., Mutch, D. & Wendl, M. C., Dec 1 2022, In: Nature communications. 13, 1, 7566.

  Research output: Contribution to journal › Comment/debate

  Open Access

• Author Correction: Inferring structural variant cancer cell fraction (Nature Communications, (2020), 11, 1, (730), 10.1038/s41467-020-14351-8)

  PCAWG Evolution and Heterogeneity Working Group, PCAWG Consortium, Fulton, L. A., Fulton, R. S., Govindan, R., Jayasinghe, R., Ley, T., Miller, C. A., Mutch, D. & Wendl, M. C., Dec 1 2022, In: Nature communications. 13, 1, 7568.

  Research output: Contribution to journal › Comment/debate

  Open Access

  • genome 100%
  • cancer 71%
  • Communication 69%
  • document markup languages 68%
  • communication 63%

• Author Correction: High-coverage whole-genome analysis of 1220 cancers reveals hundreds of genes deregulated by rearrangement-mediated cis-regulatory alterations (Nature Communications, (2020), 11, 1, (736), 10.1038/s41467-019-13885-w)

  PCAWG Transcriptome Working Group, PCAWG-Structural Variation Working Group, PCAWG Consortium, Appelbaum, E. L., Aukema, S., Fulton, L. A., Fulton, R. S., Jayasinghe, R., Ley, T., Miller, C. A., Mutch, D. & Wendl, M. C., Dec 1 2022, In: Nature communications. 13, 1, 7572.

  Research output: Contribution to journal › Comment/debate

  Open Access

  • genome 100%
  • Gene Rearrangement 89%
  • genes 89%
  • cancer 71%
  • Communication 69%

• Cells to Surgery Quiz: May 2022

  Michalski, B. M., Mutch, D. & Council, M. L., May 2022, In: Journal of Investigative Dermatology. 142, 5, p. e59-e63

  Research output: Contribution to journal › Short survey › peer-review

  Open Access

• Community access to primary care is an important geographic disparity among ovarian cancer patients undergoing cytoreductive surgery

  Zamorano, A. S., Mazul, A. L., Marx, C., Mullen, M. M., Greenwade, M., Stewart Massad, L., McCourt, C. K., Hagemann, A. R., Thaker, P. H., Fuh, K. C., Powell, M. A., Mutch, D. G., Khabele, D. & Kuroki, L. M., Dec 2022, In: Gynecologic Oncology Reports. 44, 101075.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Cytoreduction Surgical Procedures 100%
  • Ovarian Neoplasms 70%
  • Primary Health Care 60%
  • Patient Care 17%
  • Patient Readmission 17%

• Effects of the WRITE Symptoms Interventions on Symptoms and Quality of Life Among Patients With Recurrent Ovarian Cancers: An NRG Oncology/GOG Study (GOG-0259)

  Donovan, H. S., Sereika, S. M., Wenzel, L. B., Edwards, R. P., Knapp, J. E., Hughes, S. H., Roberge, M. C., Thomas, T. H., Klein, S. J., Spring, M. B., Nolte, S., Landrum, L. M., Casey, A. C., Mutch, D. G., Debernardo, R. L., Muller, C. Y., Sullivan, S. A. & Ward, S. E., May 1 2022, In: Journal of Clinical Oncology. 40, 13, p. 1464-1473 10 p.

  Research output: Contribution to journal › Article › peer-review

  • Ovarian Neoplasms 100%
  • Quality of Life 70%
  • Nurses 59%
  • Symptom Assessment 31%
  • Postal Service 30%
  5 Scopus citations

• GAS6/AXL Inhibition Enhances Ovarian Cancer Sensitivity to Chemotherapy and PARP Inhibition through Increased DNA Damage and Enhanced Replication Stress

  Mullen, M. M., Lomonosova, E., Toboni, M. D., Oplt, A., Cybulla, E., Blachut, B., Zhao, P., Noia, H., Wilke, D., Rankin, E. B., Kuroki, L. M., Hagemann, A. R., Hagemann, I. S., McCourt, C. K., Thaker, P. H., Mutch, D. G., Powell, M. A., Mosammaparast, N., Vindigni, A. & Fuh, K. C., Feb 2022, In: Molecular Cancer Research. 20, 2, p. 265-279 15 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Ovarian Neoplasms 100%
  • DNA Damage 95%
  • Homologous Recombination 82%
  • Carboplatin 82%
  • Poly(ADP-ribose) Polymerase Inhibitors 72%
  12 Scopus citations

• GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis

  Bruce, S. F., Cho, K., Noia, H., Lomonosova, E., Stock, E. C., Oplt, A., Blachut, B., Mullen, M. M., Kuroki, L. M., Hagemann, A. R., McCourt, C. K., Thaker, P. H., Khabele, D., Powell, M. A., Mutch, D. G., Shriver, L. P., Patti, G. J. & Fuh, K., Aug 2022, In: Molecular Cancer Therapeutics. 21, 8, p. 1348-1359 12 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Glycolysis 100%
  • Endometrial Neoplasms 97%
  • Paclitaxel 96%
  • Drug Therapy 48%
  • Neoplasms 30%
  5 Scopus citations

• Gynecologic oncology patient perspectives and knowledge on advance care planning: A quality improvement intervention

  Huepenbecker, S. P., Lewis, S., Valentine, M. C., Palisoul, M. L., Thaker, P. H., Hagemann, A. R., McCourt, C. K., Fuh, K., Powell, M. A., Mutch, D. G. & Kuroki, L. M., Oct 2022, In: Gynecologic Oncology Reports. 43, 101060.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Advance Care Planning 100%
  • Quality Improvement 69%
  • Oncologists 19%
  • Needs Assessment 15%
  • Outpatients 10%
  1 Scopus citations

• High visceral fat to subcutaneous fat ratios portend a poor prognosis in patients with advanced endometrial cancer

  Buckley, E., Mullen, M. M., Nizamuddin, R. A., Stein, J. H., Kuroki, L. M., Fuh, K. C., Hagemann, A. R., McCourt, C. K., Mutch, D., Khabele, D., Powell, M. A., Ippolito, J. E. & Thaker, P. H., Dec 2022, In: Gynecologic oncology. 167, 3, p. 496-501 6 p.

  Research output: Contribution to journal › Article › peer-review

  • Subcutaneous Fat 100%
  • Intra-Abdominal Fat 99%
  • Endometrial Neoplasms 91%
  • Survival 14%
  • Adiposity 9%
  2 Scopus citations

• Identification of Patients with Ovarian Cancer Experiencing the Highest Benefit from Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study

  You, B., Purdy, C., Copeland, L. J., Swisher, E. M., Bookman, M. A., Fleming, G., Coleman, R., Randall, L. M., Tewari, K. S., Monk, B. J., Mannel, R. S., Walker, J. L., Cappuccini, F., Cohn, D., Muzaffar, M., Mutch, D., Wahner-Hendrickson, A., Martin, L., Colomban, O. & Burger, R. A., Dec 1 2022, In: Journal of Clinical Oncology. 40, 34, p. 3965-3974 10 p.

  Research output: Contribution to journal › Article › peer-review

  • Bevacizumab 100%
  • Validation Studies 99%
  • Ovarian Neoplasms 81%
  • Progression-Free Survival 45%
  • Survival 33%
  9 Scopus citations

• Impact of the COVID-19 pandemic on referral to and delivery of gynecologic oncology care

  Bruce, S. F., Huysman, B., Bharucha, J., Massad, L. S., Mullen, M. M., Hagemann, A. R., Fuh, K. C., McCourt, C. K., Thaker, P. H., Khabele, D., Powell, M. A., Mutch, D. G. & Kuroki, L. M., Feb 2022, In: Gynecologic Oncology Reports. 39, 100928.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Pandemics 100%
  • Referral and Consultation 69%
  • Oncologists 29%
  • Appointments and Schedules 21%
  • Neoplasms 21%
  6 Scopus citations

• Improving Risk Assessment for Metastatic Disease in Endometrioid Endometrial Cancer Patients Using Molecular and Clinical Features: An NRG Oncology/Gynecologic Oncology Group Study

  Casablanca, Y., Wang, G., Lankes, H. A., Tian, C., Bateman, N. W., Miller, C. R., Chappell, N. P., Havrilesky, L. J., Wallace, A. H., Ramirez, N. C., Miller, D. S., Oliver, J., Mitchell, D., Litzi, T., Blanton, B. E., Lowery, W. J., Risinger, J. I., Hamilton, C. A., Phippen, N. T., Conrads, T. P., & 7 othersMutch, D., Moxley, K., Lee, R. B., Backes, F., Birrer, M. J., Darcy, K. M. & Maxwell, G. L., Sep 2022, In: Cancers. 14, 17, 4070.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Endometrial Neoplasms 100%
  • Risk Assessment 81%
  • Neoplasm Metastasis 60%
  • RNA Sequence Analysis 54%
  • Progression-Free Survival 22%
  1 Scopus citations

• Management and prognosis of cervical cancer patients treated with definitive radiation therapy who have partial metabolic response on post-therapy positron emission tomography

  Mckinnish, T. R., Greenwade, M. M., Wilkinson-Ryan, I., Schwarz, J. K., Powell, M. A., Mutch, D. G., Massad, L. S., Grigsby, P. W., Siegel, B. A. & Thaker, P. H., Jul 2022, In: Gynecologic oncology. 166, 1, p. 173-180 8 p.

  Research output: Contribution to journal › Article › peer-review

  • Positron-Emission Tomography 100%
  • Uterine Cervical Neoplasms 98%
  • Radiotherapy 74%
  • Radiation 70%
  • Biopsy 40%

• Overall survival in patients with FIGO stage IVA cervical cancer

  Schiff, J. P., Mintz, R., Cohen, A. C., Huang, Y., Thaker, P., Massad, L. S., Powell, M., Mutch, D., Schwarz, J. K., Markovina, S. T. & Grigsby, P. W., Aug 2022, In: Gynecologic oncology. 166, 2, p. 292-299 8 p.

  Research output: Contribution to journal › Article › peer-review

  • Uterine Cervical Neoplasms 100%
  • Survival 60%
  • Radiotherapy 37%
  • Progression-Free Survival 36%
  • Drug Therapy 31%
  2 Scopus citations

• Patient reported outcomes for cisplatin and radiation followed by carboplatin/paclitaxel versus carboplatin/paclitaxel for locally advanced endometrial carcinoma: An NRG oncology study

  Matulonis, U. A., Huang, H. Q., Filiaci, V. L., Randall, M., DiSilvestro, P. A., Moxley, K. M., Fowler, J. M., Powell, M. A., Spirtos, N. M., Tewari, K. S., Richards, W. E., Nakayama, J. M., Mutch, D. G., Miller, D. S., Matei, D. & Wenzel, L. B., Feb 2022, In: Gynecologic oncology. 164, 2, p. 428-436 9 p.

  Research output: Contribution to journal › Article › peer-review

  • Carboplatin 100%
  • Patient Reported Outcome Measures 98%
  • Endometrial Neoplasms 91%
  • Paclitaxel 90%
  • Cisplatin 80%
  2 Scopus citations

• Phase I Trial of Stereotactic MRI-Guided Online Adaptive Radiation Therapy (SMART) for the Treatment of Oligometastatic Ovarian Cancer

  Henke, L. E., Stanley, J. A., Robinson, C., Srivastava, A., Contreras, J. A., Curcuru, A., Green, O. L., Massad, L. S., Kuroki, L., Fuh, K., Hagemann, A., Mutch, D., McCourt, C., Thaker, P., Powell, M., Markovina, S., Grigsby, P. W., Schwarz, J. K. & Chundury, A., Feb 1 2022, In: International Journal of Radiation Oncology Biology Physics. 112, 2, p. 379-389 11 p.

  Research output: Contribution to journal › Article › peer-review

  • radiation therapy 100%
  • cancer 93%
  • Ovarian Neoplasms 90%
  • Radiotherapy 69%
  • Organs at Risk 63%
  23 Scopus citations

• Quantification of ovarian lesion and fallopian tube vasculature using optical-resolution photoacoustic microscopy

  Leng, X., Kou, S., Lin, Y., Hagemann, A. R., Hagemann, I. S., Thaker, P. H., Kuroki, L. M., McCourt, C. K., Mutch, D. G., Siegel, C., Powell, M. A. & Zhu, Q., Dec 2022, In: Scientific reports. 12, 1, 15850.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Fallopian Tubes 100%
  • Microscopy 69%
  • Blood Vessels 49%
  • Ovary 18%
  • Carbon Fiber 14%
  2 Scopus citations

• Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial

  Powell, M. A., Filiaci, V. L., Hensley, M. L., Huang, H. Q., Moore, K. N., Tewari, K. S., Copeland, L. J., Secord, A. A., Mutch, D. G., Santin, A., Warshal, D. P., Spirtos, N. M., DiSilvestro, P. A., Ioffe, O. B. & Miller, D. S., Mar 20 2022, In: Journal of Clinical Oncology. 40, 9, p. 968-977 10 p.

  Research output: Contribution to journal › Article › peer-review

  • Carcinosarcoma 100%
  • Ifosfamide 93%
  • Carboplatin 82%
  • Paclitaxel 74%
  • Uterus 68%
  28 Scopus citations

• The IARC perspective on cervical cancer screening

  Suba, E. J., Ortega, R. E. & Mutch, D. G., Feb 10 2022, In: New England Journal of Medicine. 386, 6, p. 607 1 p.

  Research output: Contribution to journal › Letter › peer-review
  1 Scopus citations

• The impact of tumor size and histology on local control when utilizing high-dose-rate interstitial brachytherapy for gynecologic malignancies

  Schiff, J. P., Mahmood, M., Huang, Y., Powell, M. A., Mutch, D., Dyk, P. T., Lin, A., Schwarz, J. K., Markovina, S. T. & Grigsby, P. W., Jun 2022, In: Gynecologic oncology. 165, 3, p. 486-492 7 p.

  Research output: Contribution to journal › Article › peer-review

  • Brachytherapy 100%
  • Histology 72%
  • Neoplasms 29%
  • Outpatients 25%
  • Adenocarcinoma 17%

• The targeted SMAC mimetic SW IV-134 augments platinum-based chemotherapy in pre-clinical models of ovarian cancer

  Binder, P. S., Hashim, Y. M., Cripe, J., Buchanan, T., Zamorano, A., Vangveravong, S., Mutch, D. G., Hawkins, W. G., Powell, M. A. & Spitzer, D., Dec 2022, In: BMC Cancer. 22, 1, 263.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • SW IV-134 100%
  • Platinum 43%
  • Caspases 42%
  • Ovarian Neoplasms 37%
  • Mitochondria 34%
  2 Scopus citations

• TP53 Sequencing and p53 Immunohistochemistry Predict Outcomes When Bevacizumab Is Added to Frontline Chemotherapy in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study

  Thiel, K. W., Devor, E. J., Filiaci, V. L., Mutch, D., Moxley, K., Alvarez Secord, A., Tewari, K. S., Mcdonald, M. E., Mathews, C., Cosgrove, C., Dewdney, S., Aghajanian, C., Samuelson, M. I., Lankes, H. A., Soslow, R. A. & Leslie, K. K., Jun 1 2022, In: Journal of Clinical Oncology. 10, JCO.21.02506.

  Research output: Contribution to journal › Article › peer-review

  • Bevacizumab 100%
  • Endometrial Neoplasms 92%
  • Immunohistochemistry 62%
  • temsirolimus 57%
  • Drug Therapy 52%
  13 Scopus citations

• Tumor Lysis Syndrome in a Patient With Metastatic Endometrial Cancer Treated With Lattice Stereotactic Body Radiation Therapy

  Schiff, J. P., Spraker, M. B., Duriseti, S., Shaikh, S., Murad, H. F., Mutch, D. G., Robinson, C. G., Kavanaugh, J. & Lin, A. J., Jan 1 2022, In: Advances in Radiation Oncology. 7, 1, 100797.

  Research output: Contribution to journal › Article › peer-review

  Open Access
  4 Scopus citations